Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
23:38:24 EDT Tue 25 Mar 2025
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

Q:NKTR - NEKTAR THERAPEUTICS - https://www.nektar.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
NKTR - Q20.40.82·4.000.10.8373-0.0233-2.71,476.59384,2360.8601  0.89  0.8121.928  0.6519:09:53Mar 2015 min RT 2¢

Recent Trades - Last 10 of 4236
Time ETExPriceChangeVolume
19:09:53Q0.8549-0.005710
18:47:44Q0.83-0.030640
18:45:21Q0.83-0.03061
17:56:37Q0.855-0.005656
17:49:54Q0.8301-0.03051
17:20:43Q0.8228-0.037850
17:08:15Q0.855-0.005650
16:31:10Q0.8599-0.000757
16:14:57Q0.86830.007740
16:06:18Q0.8301-0.03051,100

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-03-20 18:00U:NKTRNews ReleaseNektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference
2025-03-12 16:15U:NKTRNews ReleaseNektar Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
2025-03-05 18:00U:NKTRNews ReleaseNektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2024 on Wednesday, March 12, 2025, After Close of U.S.-Based Financial Markets
2025-02-26 07:00U:NKTRNews ReleaseNektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AA Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Severe-to-Very Severe Alopecia Areata
2025-02-24 07:00U:NKTRNews ReleaseNektar Announces Clinical Trial Agreement to Evaluate Rezpegaldesleukin in Patients with New Onset Type 1 Diabetes Mellitus
2025-02-24 07:00U:NKTRNews ReleaseNektar Therapeutics to Host Virtual Investor & Analyst Event with Type 1 Diabetes Experts on February 24th
2025-02-10 07:00U:NKTRNews ReleaseNektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Moderate-to-Severe Atopic Dermatitis
2025-01-10 07:00U:NKTRNews ReleaseNektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AD Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Moderate-to-Severe Atopic Dermatitis
2024-12-07 12:00U:NKTRNews ReleaseNektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma at the 66th Annual ASH Meeting
2024-11-18 15:30U:NKTRNews ReleaseNektar Therapeutics Presents First Preclinical Data from Novel CSF-1 Program, NKTR-422, at 2024 American College of Rheumatology (ACR) Convergence
2024-11-07 16:15U:NKTRNews ReleaseNektar Therapeutics Reports Third Quarter 2024 Financial Results
2024-11-07 10:15U:NKTRNews ReleaseNektar and Collaborators Present Late-breaking Results from Phase 2 Study of NKTR-255 for the Treatment of Radiation Induced Lymphopenia in Locally Advanced Non-Small Cell Lung Cancer Patients at Society for Immunotherapy of Cancer (SITC) Annual Meeting
2024-11-06 18:00U:NKTRNews ReleaseNektar Therapeutics to Participate in Upcoming Investor Conferences
2024-11-04 08:30U:NKTRNews ReleaseNektar Announces Definitive Agreement with Ampersand Capital Partners to Sell Its Commercial PEGylation Reagent Manufacturing Business in Alabama
2024-10-31 18:00U:NKTRNews ReleaseNektar to Announce Financial Results for the Third Quarter 2024 on Thursday, November 7, 2024, After Close of U.S.-Based Financial Markets
2024-10-29 09:00U:NKTRNews ReleaseNektar Announces Publication in Nature Communications of Results from Phase 1b Studies of Rezpegaldesleukin in Two Inflammatory Skin Diseases
2024-10-17 12:07U:NKTRNews ReleaseNektar Announces Publication in Blood of Phase 1 Data for Novel IL-15 Agonist NKTR-255 in Combination with Autologous CD19-22 CAR-T Cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia
2024-09-25 03:30U:NKTRNews ReleaseNektar Therapeutics Announces Multiple Presentations for Rezpegaldesleukin at EADV 2024
2024-09-03 09:00U:NKTRNews ReleaseNektar Management to Present at Upcoming Investor Conferences
2024-08-08 16:15U:NKTRNews ReleaseNektar Therapeutics Reports Second Quarter 2024 Financial Results